Gut reaction
The case against antibiotic use in livestock rests largely on drug resistance observed in food-bome pathogens such as Salmonella or Campylobacter, which often infect animals without causing symptoms. First, microbial sleuths must link a livestock antibiotic to a drug:1esit*, strain. Next, they must show that the strain can survive the slaughterhouse. Finally, to cement the connection to human illness, they must prove that eating tainted meat leads to an infection that defies antibiotic treatment. The last link is the hardest to verify. "That's where the chain of evidence starts to get fraye{' Sa$ers says.
Luckily for the Danish team, the deadly bug did not take them by surprise. It's a variant of S almone ll a typ himurium DT104, a strain that resists five common antibiotics and had flared up in many European countries-but rarely in Denmark. Hoping to keep it at bay, Danish officials set up in 1997 what Wegener calls the world's most aggressive surveillance system for resistant Salmonella. They test for drug resistance in every Danish patient who sees a doctor for a Salmonella infection, about 3200 people a Wallowing in bacteria, After a vicious strain of drug-resistant Salmonella kitted two people in Denmark in 1998, scientists traced the bug to a single herd of Danish pigs. The strain, they found, was resistant to a livestock antibiotic similar to the human drug that faited to cure the victims.
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Superbugs on the Hoof?
When the severe diarrhea didn't stoo after nine awful days, the 62-year-old. Danish woman dragged herself to the emergency room at Bispebjerg Hospital in Copenhagen. The diagnosis was a cinch: foodpoisoning from Salmonella. Doctors rolled out their big gun, an antibiotic called ciprofloxacin that can vanquish the nastiest Salmonella strains in a few days. But as the hours passed, the infection worsenedbecoming so bad that the Salmonella punched a hole in her colbn, allowing it and other bacteria to invade the rest of her body. As the situation grew desperate, doctors blasted her with heavy doses of two more antibiotics and stitched up her damaged colon. The drugs knocked offthe Salmonel-/a, but other escapees from the gut sent her into septic shock; one by one, her organs failed. Four days after doctors realized the Salmonella was impervious to ciprofloxacin, she was dead.
The Danish woman was not the first person to succumb to a superbug resistant to antibiotics. But she and another Salmonella victim in the summer of 1998 put a human face on an alarming hend: pathogens rapidly acquiring resistance to drugs that are similar to antibiotics used for years to treat livestock. In a nice piece of detective work, a team led by microbiologist Henrik Wegener of the Danish Veterinary Laboratorv in Copenhagen traced the drug-resistant strain of Salmonella to infected swine. To fisht Salmonella outbreaks, some farmers h-ad been dosing herds with enrofloxacin. It tums out that this drug and ciprofloxacin belong to a class of comporurds called quinolones that gum up bacterial machinery for replicating DNA. The researchers traced the deadly strain to contaminated pork products from a single Danish herd. The findings, reported last November tn The New England Journal of Medicine 0\\EJM), are the strongest indictnent yet implicating livestock antibiotics in human deaths. Says microbiologist Abigail Salyers of the iJniversity of-Illinois, Urbana-Champaign: "It's the closest that anybody has come to a smoking gun." And just last week, researchers reported evidence linking a case involving a resistant Salmonella strain in the United States to the use of animal antibiotics.
For decades farmers have mostly had free rein in dosing livestock with antibiotics are taking the threat quite seriously, as is the When word came on 18 June 1998 that a British Royal Society of Medicine, which quinolone-resistant strain had shown up in a brought experts together in Washington, hog slaughterhouse on the island of Zealan{ D.c., this week to brainstorm on the issue KAre Mslbak of copenhagen's statens andJo gducate the public. Although drug use Serum Institute leaped to action. By coinci-= on the farm may have little to do with drug-dence, earlier that day his team had identi-B resistant tuberculosis or other pathogens fied samples of a vicious DTl04 strain in 5 transmitted from person to person, it "has ev-five Danish patients. This strain, and the one f; erything to do with bacteria acquired through in the slaughterhousen beat back the same E seven drugs-fwo more than other DT104 strains. Mslbak's team started phoning patients, slaughterhouse workers, and meat wholesalers. By nightfall they learned that all the patients had bought pork fiom shops supplied by the Zealand slaughterhouse.
"That made the hypothesis simple," says Wegener, who was consulting with Mslbak throughout the day: The pork was the source of the super DT104. Records later showed thatjust one ofthe 37 herds slaughtered for that shipment was infected by the resistant strain. Although the herd had not been treated with quinolones that year, others on nearby farms had" and Salmonella can easily jump from herd to herd, Wegener says. What's more, DNA fingerprinting showed that the drug-resistance genes in the patients were identical to those in the pigs. Now another case, reported in last week's NEJM, suggests that a second new drug agarnst Salmonellahas been compromised by a livestock antibiotic. Bacteriologist Paul Fey of the University ofNebraska Medical Center in Omaha and his colleagues described how a l2-year-old Nebraska boy became infected by the same Salmonella shain as had cows on his father's ranch. Apparently, says Fey, the cows had contracted the resistant Salmonella from a ceftiofur-treated herd on another ranch. When the boy became ill, doctors treated him with ceftriaxone, an antibiotic similar to ceftiofru. The boy recovered-but not thanks to the ceftriaxone, which hardly dented the Salmonella. The strain was resistant. That worries Fey, as doctors already have their hands tied when treating childhood Salmonella'. Front-line quinolones can't be used because they impede bone development. Thatb why Fey predicts "dire consequences" for children's health if the ceftriaxoneresistant strains spread.
Even in the absence of a direct link between farm and table, circumstantial evidence can be damning. Spurning the CDC's advice, the FDA in 1994 approved the use of quinolones for preventing infections ofan intestinal bacterium, Campylobacter jejuni, n poultry. Since then, the percentage of quinolone-resistant Campylobacler cultures in routine sampling in people has sklrocketed from 1% to 17ohn jusrT years, Kirk Smith of the Minnesota Departrnent of Public Health and his colleagues revealed lastyear wNEIM. Campylobacter very rarely kills people, Smith savs. "but it's a severe enoush illness that 3 you'.. just hating life." And it shows that i Salmonella isn't the only bug to worry about. Vancomycin resistance already is a huge problem in the United States. The drug has been used for years in hospitals, allowing bugs to develop resistance. But that doesn't explain why resistance is cropping up in healthy people in Europe, resistance, the European Union banned avoparcin n 1997 .
A team led by molecular microbiologist Rob Willems of the Dutch National Institute of Public Health and the Environment in Bilthoven has evidence that such gene transfers are occurring. The researchers found identical sequences of transposons-DNA snippets that can jump {iom one bacterium to another-with identical resistance genes in enterococci from people and from pigs. These transposons are different from ones found in resistant enterococci from cows, chickens, and turkeys, the researchers report in the March 1999 issue of Antimicrobial Agents and Chemotherapy. That suggests the resistance moved from pigs to humans, Willems says.
One obvious question is whether cutting down on antibiotics on the farm can throttle resistant pathogens. New research suggests that's the case. ln a report in the March issue Human disease Deadly pas de deux. Usually a kind of bacteria called enterococci dwett peaceably in our gut. But new findings suggest that drug-resistant bacteria in contaminated food or water can slip enterococci the genes conferring resistance. For people with weakened immune systems who are susceptible to enterococci infection, the drug-resistant enterococci pose a grave threat. of the Journal of Antimicrobial Chemotherapy, a group led by veterinary microbiologist Anthony van den Bogaard of the University of Maastricht in the Netherlands showed that by 1999, 2 years after avoparcin was taken off the market in Europe, the prevalence of vancomycin-resistant strains in pigs, chickens, and people in the Netherlands had dropped to halfthe 1997 levels.
Cutling the antibiotic herd To guard against the nightmare of animal enterococci or other bugs planting the seeds of resistance in more dangerous pathogens, goverffnents worldwide are cracking down on the use of drugs in livestock. The first moves came after a British panel in 1969 recommended banning growth-promoting says microbiologist Wolfgang Witte of the Robert Koch Institute in Wernigerude, Germany. The evidence suggests another reason: In 1974, the European Union approved the use of avoparcin, an antibiotic that, by an unknorur mechanism, makes livestock grow fatter on less feed. Avoparcin and vancomycin kill bacteria by blocking an en-4lme essential for building the cell wall. Not surprisingly, enterococci in livestock that resist avoparcin also can withstand vancomycin. Despite sfrict procedures, enterococci {iom the gut on occasion infect meat during slaughter. If a person eats undercooked meat tainted with resistant enterococci, the livestock strain can transfer to the human strain the genes conferring resistance to vancomycin. Alarmed by the potential link between avoparcin and vancomycin www.sciencemag.org SCIENCE VOL 288 5 MAY 2000 antibiotics that spur resistance to drugs used in human medicine. The panel's advice was partly heeded in Europe, where key antibiotics like penicillin and tehacycline were taken out of agricultural use in the 1970s.
But it has been mostly ignored in the United States, where industy officials insist that antibiotics keep animals healthy and thus safeguard the food supply. "While there's a theoretical link fbetween resistant shains in livestock and people], we think that there's so many things that need to happen that the risk is diminishingly small," says the Animal Health Institute's Carnevale. Even if antibiotic use on the farm does pose a threat, it pales in comparison with the scourge of resistance from human medical practices, says Robin Rywater, a Reigate, U.K., consultant for Pfizer, which produces animal antibiotics. Besides, Bywater says, the drug-resistant pathogens most dangerous to people-such as Staphylococctn aureus or the tuberculosis bacterium--{o not infect livestock.
The main skirmishes now are over the practice ofusing low doses ofantibiotics to make livestock fatter on less feed. Th,ree years ago, the World Health Organization argued for phasing out use ofantibiotics for this purpose, if the animal drugs are used in people or breed resistance to human drugs that work by a similar mechanism. The European Union agreed and barured the use ofavoparcin and four other drugs as growth promoters.
The FDA, meanwhile, has given mixed signals regarding so-called subtherapeutic uses-growth promotion and illness prevention-of animal antibiotics. In a series of actions since 1994, the agency has approved the use ofquinolones to treat and prevent infections in poultry and beef cattle. But in 1998 it floated draft regulations that would raise the bar for all uses of new animal antibiotics. The regulations would require companies to carry out resistance studies before and after a drug's approval, and to pull any drug from the market if the target bacteria develop resistance to human antibiotics. "We're most concerned about those pathogens for which the disease is serious in humans and for which the drug we're considering may be the drug of last resort," such as quinolone-resistari Salmonella and vancomycin-resistant enterococci, says Stephen Sundlof, director of the FDA's Center for Veterinary Medicine. "The only scientific way we have to do it is to look at it on a case-by-case basis."
Congress, howeveg may prod the FDA into a more aggressive stance. A bill inhoduced last year by Representative Sherrod Brown (D-OI| would order companies to discontinue using seven antibiotics for any reason other than to treat illness in animals-unless the industry proves that the drugs won't harm human health. Brown N EWS FOCUS hopes the bill, opposed by the agriculture industry, will pass n2 or 3 years. "The burden should be on the drug industry to prove that they are safe, not on the FDA to prove 100% that they are unsafe," hetold, Science.
Researchers arc also trying to provide industy with alternatives to antibiotics that can keep livestock healthy. These include probiotics, in which healthy gut bacteria are infused into animals before they are weaned to crowd out pathogens; vaccines; and animal husbandry practices that prevent infections from spreading from farm to farm. Aithough these possibilities hold promise, 'there is no i..__ jt one magic bullet' in the pipeline, says microbiologist Paula Fedorka-Cray of the U.S. Born and raised in India, and educated at one ofthe six elite tndian Institutes ofTechnology (trT), they had decided it was time to give something back to their native country. In particular, they had come to seek Vajpayeeb blessing for a bold plan to raise numbers and calculated the cost to modemize the institutes at $l billion. Unfazed by the sum, the self-made multimillionaires said OK. but under two conditions: The money, to be raised over 6 years, would go directly to the IITs, and an independent board of trustees, made up of the country's business and academic elite, would replace the government as overseer. Vajpayee said he'd look into it. These high-tech tycoons are part of a startling new tend in India. Even as they begin passing the hat for the IITs, another group of Indian-bom, U.S.-based software engineers led by Pumendu Chattet'ee, managing director of the NewYork-tased Chatte{ee Group, wants to raise the same amount-$l billion-$500 million from wealthy IIT alumni like themselves for new buildings, equipment, and p{ogxams at their alma maters.
The prime minister was delighted, but qrged them to think even bigger: "He said, why not pick up the entire tab?" recalls Kanwal S. Rekhi, the retired technology chief at Novell lnc., who now runs a small to set up a series of world-class centers of California company, IndUS Entrepreneurs, higher leaming in India (Science,3l March, that fosters collaborations between the fwo p.2389). And individual expatriate Indians democracies. The startled executives ran the are donating to other high+ech causes back
